Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-06-21
2011-06-21
Yu, Misook (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
Reexamination Certificate
active
07964705
ABSTRACT:
This invention relates to humaneered anti-factor B antibodies and antigen-binding fragments thereof with reduced immunogenicity. The humaneered anti-factor B antibodies and antigen-binding fragments thereof are derived from murine monoclonal antibody 1379, which binds factor B in the third short consensus repeat (“SCR”) domain and selectively inhibits activation of the alternative complement pathway by preventing formation of the C3bBb complex. The invention also relates to methods of treating diseases or disorders in which activation of the alternative complement pathway plays a role, and methods of selectively inhibiting activation of the alternative complement pathway in an individual in need thereof.
REFERENCES:
patent: 4883784 (1989-11-01), Kaneko
patent: 5679546 (1997-10-01), Ko et al.
patent: 5869615 (1999-02-01), Hourcade et al.
patent: 5976540 (1999-11-01), Rittershaus et al.
patent: 6165463 (2000-12-01), Platz et al.
patent: 6248365 (2001-06-01), Römisch et al.
patent: 6458360 (2002-10-01), Fearon et al.
patent: 6521450 (2003-02-01), Atkinson et al.
patent: 6820011 (2004-11-01), Chen et al.
patent: 6897290 (2005-05-01), Atkinson et al.
patent: 2002/0015701 (2002-02-01), Gupta-Bansal et al.
patent: 2002/0081293 (2002-06-01), Fung et al.
patent: 2003/0198636 (2003-10-01), Gupta-Bansal et al.
patent: 2003/0235582 (2003-12-01), Singh et al.
patent: 2005/0107319 (2005-05-01), Bansal
patent: 2005/0169915 (2005-08-01), Do Couto et al.
patent: 2005/0255552 (2005-11-01), Flynn et al.
patent: 2005/0260198 (2005-11-01), Holers et al.
patent: 2006/0002944 (2006-01-01), Ashkenazi et al.
patent: 2006/0134098 (2006-06-01), Bebbington et al.
patent: 2006/0178308 (2006-08-01), Schwaeble et al.
patent: 2006/0263819 (2006-11-01), Hageman et al.
patent: 2006/0292141 (2006-12-01), Holers et al.
patent: 2007/0020647 (2007-01-01), Hageman et al.
patent: 2007/0065433 (2007-03-01), Mollnes et al.
patent: 2007/0183970 (2007-08-01), Goldenberg et al.
patent: 2008/0075720 (2008-03-01), Holers et al.
patent: 2008/0102040 (2008-05-01), Holers et al.
patent: 2008/0267980 (2008-10-01), Tomlinson et al.
patent: 2009/0175847 (2009-07-01), Barghorn et al.
patent: WO-99/42133 (1999-08-01), None
patent: WO-00/21559 (2000-04-01), None
patent: WO-00/21559 (2000-04-01), None
patent: WO-01/47963 (2001-07-01), None
patent: WO-01/47963 (2001-07-01), None
patent: WO-2004/022096 (2004-03-01), None
patent: WO-2004/103288 (2004-12-01), None
patent: WO-2004/103288 (2004-12-01), None
patent: WO-2004/106369 (2004-12-01), None
patent: WO-2004/106369 (2004-12-01), None
patent: WO-2005/069970 (2005-08-01), None
patent: WO-2005/077417 (2005-08-01), None
patent: WO-2006/012621 (2006-02-01), None
patent: WO-2006/012621 (2006-02-01), None
patent: WO 2006055178 (2006-05-01), None
patent: WO-2006/062716 (2006-06-01), None
patent: WO-2006/062716 (2006-06-01), None
patent: WO-2006/083533 (2006-08-01), None
patent: WO-2006/083533 (2006-08-01), None
patent: WO-2007/011363 (2007-01-01), None
patent: WO-2007/011363 (2007-01-01), None
patent: WO-2007/029008 (2007-03-01), None
patent: WO-2007/029008 (2007-03-01), None
patent: WO-2007/032876 (2007-03-01), None
patent: WO-2007/032876 (2007-03-01), None
patent: WO-2007/056227 (2007-05-01), None
patent: WO-2007/056227 (2007-05-01), None
patent: WO-2008/140653 (2008-11-01), None
patent: WO-2008/140653 (2008-11-01), None
Mariuzza et al. (Annu. Rev. Biophys. Biophys. Chem. 1987; 16: 139-159).
Rudikoff et al (Proc. Natl. Acad. Sci. USA 1982 vol. 79: p. 1979-1983).
Giusti et al. (Proc. Natl. Acad. Sci. USA. May 1987; 84 (9): 2926-2930).
Chien et al. (Proc. Natl. Acad. Sci. USA. Jul. 1989; 86 (14): 5532-5536).
Caldas et al. (Mol. Immunol. May 2003; 39 (15): 941-952).
MacCallum et al. (J. Mol. Biol. Oct. 11, 1996; 262 (5): 732-745).
Holm et al. (Mol. Immunol. Feb. 2007; 44 (6): 1075-1084).
Cellular and Molecular Immunology (Eds. Abass et al.; 1991; W.B. Saunders: Philadelphia; p. 54).
Thurman et al (JASN, 17:707-715, 2006).
Anonymous. (Date Unknown). “Monoclonal Antibody to Human Factor B (Ba), Catalog No. A225”in Quidel Corporation Product Catalog, located at <http://www.quidel.com/products/product—detail.php?prod=82&group=2>, last visited on Aug. 4, 2008, two pages.
Anonymous. (Date Unknown). “Monoclonal Antibody to Human Factor B (Bb), Catalog No. A227,”in Quidel Corporation Product Catalog, located at <http://www.quidel.com/products/product—detail.php?group=2&prod=83>, last visited on Aug. 4, 2008, two pages.
Bendayan, M. (1995). “Possibilities of False Immunocytochemical Results Generated by the Use of Monoclonal Antibodies: The Example of the Anti-proinsulin Antibody,”J. Histochem. Cytochem. 43(9):881-886.
Bost, K.L. et al. (1988). “Antibodies Against a Peptide Sequence Within the HIV Envelope Protein Crossreacts with Human Interleukin-2,”Immunological Investigation17(6&7):577-586.
Holers, V.M. et al. (2004). “The Alternative Pathway of Complement in Disease: Opportunities for Therapeutic Targeting,”Molecular Immunology41:147-152.
Hourcade, D.E. et al. (Aug. 1995). “Analysis of the Short Consensus Repeats of Human Complement Factor B by Site-directed Mutagenesis,”J. Bio. Chem. 270(34):19716-19722.
Thurman, J.M. et al. (Feb. 1, 2003). “Lack of Functional Alternative Complement Pathway Ameliorates Ischemic Acute Renal Failure in Mice,”J. Immunol. 170:1517-1523.
Ueda, A. et al. (February 15, 1987). “Probing Functional Sites on Complement Protein B with Monoclonal Antibodies: Evidence for C3b-Binding Sites on Ba,”J. Immunology138(4):1143-1149.
Taube, C. et al. (May 23, 2006). “Factor B of the Alternative Complement Pathway Regulates Development of Airway Hyperresponsiveness and Inflammation,”Proc. Natl. Acad. Sci. USA103(21):8084-8089.
Lederman, S. et al. (1991). “A Single Amino Acid Substitution in a Common African Allele of the CD4 Molecule Ablates Binding of the Monoclonal Antibody, OKT4,”Molecular Immunology28(11):1171-1181.
Li, C.H. et al. (Jun. 1980). “β-Endorphin Omission Analogs: Dissociation of Immunoreactivity from Other Biological Activities,”Proc. Nat'l Acad. Sci USA77(6):3211-3214.
Chardès, T. et al. (1999). “Efficient Amplification and Direct Sequencing of Mouse Variable Regions from any Immunoglobulin Gene Family,”FEBS Lett. 452(3):386-394.
Choi, W.S. et al. (Sep. 25, 2001). “Inhalation Delivery of Proteins from Ethanol Suspensions,”Proc. Natl. Acad. Sci. 98(20):11103-11107.
Clardy, C.W. et al. (Apr. 1992). “In Vitro Inhibition of Complement Activation Using a Monoclonal Antibody (McAb) Directed Against Human Factor B (FB),”Pediatric Res. 31(4-pt 2):331A, Abstract No. 1969.
Clardy, C.W. et al. (Oct. 1994). “Complement Activation by Whole Endotoxin is Blocked by a Monoclonal Antibody to Factor B,”Infect. Immunity62(10):4549-4555.
Girardi, G. et al. (Dec. 2003). “Complement C5a Receptors and Neutrophils Mediate Fetal Injury in the Antiphospholipid Syndrome,”J. Clin. Invest. 112(11):1644-1654.
Girardi, G. et al. (Feb. 2004). “Complement C5a Receptors and Neutrophils Mediate Fetal Injury in the Antiphospholipid Syndrome,” corrigendumJ. Clin. Invest. 113(4):646.
Glovsky, M.M. et al. (Dec. 2004). “Complement Determinations in Human Disease,”Annals of Allergy, Asthma, and Immunology93(6):513-523 & 605.
Kolb, W.P. et al. (1989). “Ba and Bb Fragments of Factor B Activation: Fragment Production, Biological Activities, Neoepitope Expression and Quantitation in Clinical Samples,”Complement&Inflammation6:175-204.
Stribling, R. et al. (Dec. 1992). “Aerosol Gene Delivery In Vivo,”Proc. Natl. Acad. Sci. USA89:11277-11281.
Tanaka, E. et al. (Aug. 1991). “Murine Monoclonal Anti-Ba Antibody that Enhances Haemolytic Activity of Factor B,”Immunol. 73(4):383-387.
Tatusova, T.A. et al. (May 15, 1999). “BLAST 2 Seque
Emlen Woodruff
Flynn Peter
Holers V. Michael
Duffy Brad
Morrison & Foerster / LLP
Taligen Therapeutics, Inc.
Yu Misook
LandOfFree
Humaneered anti-factor B antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humaneered anti-factor B antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humaneered anti-factor B antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2682127